Handwriting Analysis in Movement Disorders

Parkinson Disease Clinical Trial

— HANDWRML  

Official title:

Advanced Machine Learning Analysis of Handwriting in Patients With Movement Disorders

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05355480
• Other study ID #: NEUR_04
• Status: Recruiting
• Start date: December 1, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: March 2023
• Source: Neuromed IRCCS
• Contact: Antonio Suppa, MD
• Phone: +00390649914074
• Email: antonio.suppa[@]uniroma1.it
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Handwriting is a complex cognitive prowess that deteriorates in patients affected by neurodegenerative diseases, including movement disorders. More in detail, patients with Parkinson's disease (PD) may manifest prominent handwriting abnormalities which have been collectively identified as parkinsonian micrographia. MIcrographia may manifest at the onset of the disease and then worsens progressively with time. Previous techniques released to investigate micrographia in PD relied on perceptual analysis of simple tasks or were based on expensive technological tools, including tablets. However, handwriting can be promptly collected in an ecological scenario, through safe, cheap, and largely available tools. Also, the objective handwriting analysis through artificial intelligence would represent an innovative strategy even superior to previous techniques, since it allows for the analysis of large amounts of data. In this experimental project, the investigators apply a specific machine learning algorithm to analyze handwriting samples recorded in healthy controls and PD patients. The study aims to verify whether the technique proposed by the investigators would be able to detect parkinsonian micrographia objectively, monitor the evolution of handwriting abnormalities and assess the symptomatic improvement of handwriting following L-Dopa administration in PD patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: December 31, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• Healthy conditions

• clinical diagnosis of Parkinson's disease

Exclusion Criteria:

• cognitive decline

Related Conditions & MeSH terms

• Disease
• Movement Disorders
• Parkinson Disease

Locations

Country	Name	City	State
Italy	IRCCS Neuromed	Pozzilli

Sponsors (1)

Lead Sponsor	Collaborator
Neuromed IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Stroke size of handwriting characters	height of single letters	through study completion, an average of 1 year